Skip to main content
Fig. 6 | Journal of Hematology & Oncology

Fig. 6

From: Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers

Fig. 6

TDCC assay using HUB-02-B2-055 colorectal cancer organoid model. A Mean background corrected Caspase3/7 fluorescence intensity from T0 (i.e., 0 h, baseline) to 60 h of co-culture in the presence of anti-CD3 and NILK-2301 plotted per antibody condition for the following concentrations: 0.3 μg/mL (top panel), 1 μg/mL (middle panel) and 5 μg/mL (bottom panel). B Representative images at 60 h of co-culture condition with 5 μg/mL NILK-2301. Corresponding mean background corrected Caspase3/7 fluorescence intensity values with their standard deviations are shown in Additional file 1: Table S3. BF, brightfield. Scale bar 500 μm

Back to article page